EUVIMEDEUVIMED entdecken
Crossref

Intratympanic Gentamicin Injection in Ménière’s Disease: Our Ten Years’ Experience and Outcomes

Barbara Filosa, Antonio Trusio, Generoso De Cristofaro, Pasquale Marra, Giuseppe Malafronte

International Journal of Applied Biology and Pharmaceutical Technology · 2023

DOI: 10.26502/ijabpt.202121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Applied Biology and Pharmaceutical Technology, 2023. Verfasst von Barbara Filosa und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of our study is to evaluate the effectiveness of intratympanic gentamicin injection (ITG) on vertigo control with reduced doses and its hearing effects. Materials and Method: The study was conducted at Otolaryngology Department of AORN “S.G. Moscati” between January 2005 and January 2015 on 72 patients with disabling unilateral Meniere’s disease. We use 0.2-0.3 mL of gentamicin sulfate at a concentration of 40mg/ml, injected into the affected ear through the posterior-inferior quadrant of the tympanic membrane. The procedure was carried out for three following days. Main outcome measures: vertigo control and hearing threshold changes after ITG treatment.

Results

In 98.6% of the patients(n=71) the ITG produced the full remission of the vertiginous symptoms. In 91.6% of cases(n=66) a single treatment (three consequent injections) was sufficient to control vertigo, in 5.5% of cases(n=4) two treatments were necessary to control vertigo and in 1.3% of patients(n=1) three treatments were necessary to control vertigo. In no case we have had hearing loss after ITG procedure. The pre-treatment pure tone average was 48db. The post-treatment pure tone average was 49.2db. This difference was no statistical difference.

Conclusion

In this study we reported high vertigo control, long follow-up and no case of significant hearing worsening. We consider the three injections in the following three days with low doses of gentamicin a safe and valid treatment for Meniere’s disease.

Zitieren

APA

Filosa, B., Trusio, A., Cristofaro, G. D., Marra, P., & Malafronte, G. (2023). Intratympanic Gentamicin Injection in Ménière’s Disease: Our Ten Years’ Experience and Outcomes. International Journal of Applied Biology and Pharmaceutical Technology. https://doi.org/10.26502/ijabpt.202121

Vancouver

Filosa B, Trusio A, Cristofaro GD, Marra P, Malafronte G. Intratympanic Gentamicin Injection in Ménière’s Disease: Our Ten Years’ Experience and Outcomes. International Journal of Applied Biology and Pharmaceutical Technology. 2023. doi:10.26502/ijabpt.202121

BibTeX
@article{Filosa2023,
  author = {Filosa, Barbara and Trusio, Antonio and Cristofaro, Generoso De and Marra, Pasquale and Malafronte, Giuseppe},
  title = {Intratympanic Gentamicin Injection in Ménière’s Disease: Our Ten Years’ Experience and Outcomes},
  journal = {International Journal of Applied Biology and Pharmaceutical Technology},
  year = {2023},
  doi = {10.26502/ijabpt.202121}
}
Kostenlos starten →